246 related articles for article (PubMed ID: 22718320)
61. Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α) as a Regulator of the Angiogenic Profile of Endometriotic Lesions.
Pergialiotis V; Frountzas M; Fasoulakis Z; Daskalakis G; Chrisochoidi M; Kontzoglou K; Perrea DN
Cureus; 2022 Feb; 14(2):e22616. PubMed ID: 35371629
[TBL] [Abstract][Full Text] [Related]
62. Hormonal therapies for endometriosis: implications for bone metabolism.
Dawood MY
Acta Obstet Gynecol Scand Suppl; 1994; 159():22-34. PubMed ID: 8209669
[TBL] [Abstract][Full Text] [Related]
63. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis.
Rudzitis-Auth J; Menger MD; Laschke MW
Hum Reprod; 2013 May; 28(5):1339-47. PubMed ID: 23427233
[TBL] [Abstract][Full Text] [Related]
64. Medical treatment of endometriosis.
Huang HY
Chang Gung Med J; 2008; 31(5):431-40. PubMed ID: 19097589
[TBL] [Abstract][Full Text] [Related]
65. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy.
Dulak J; Józkowicz A
Curr Cancer Drug Targets; 2005 Dec; 5(8):579-94. PubMed ID: 16375664
[TBL] [Abstract][Full Text] [Related]
66. Augmented Angiogenic Factors Expression via FP Signaling Pathways in Peritoneal Endometriosis.
Rakhila H; Al-Akoum M; Doillon C; Lacroix-Pépin N; Leboeuf M; Lemyre M; Akoum A; Pouliot M
J Clin Endocrinol Metab; 2016 Dec; 101(12):4752-4763. PubMed ID: 27726474
[TBL] [Abstract][Full Text] [Related]
67. State of the art, new treatment strategies, and emerging drugs for non-hormonal treatment of endometriosis: a systematic review of randomized control trials.
Mikuš M; Vitale SG; Ćorić M; Zajec V; Ciebiera M; Carugno J; D'alterio MN; Herman M; Puževski T; Angioni S
Gynecol Endocrinol; 2022 Nov; 38(11):911-917. PubMed ID: 36237165
[No Abstract] [Full Text] [Related]
68. Novel therapies targeting endometriosis.
Taylor HS; Osteen KG; Bruner-Tran KL; Lockwood CJ; Krikun G; Sokalska A; Duleba AJ
Reprod Sci; 2011 Sep; 18(9):814-23. PubMed ID: 21693775
[TBL] [Abstract][Full Text] [Related]
69. New therapeutic approaches for endometriosis besides hormonal therapy.
Chen FY; Wang X; Tang RY; Guo ZX; Deng YZ; Yu Q
Chin Med J (Engl); 2019 Dec; 132(24):2984-2993. PubMed ID: 31809322
[TBL] [Abstract][Full Text] [Related]
70. Endometriosis 1990. Current treatment approaches.
Barbieri RL
Drugs; 1990 Apr; 39(4):502-10. PubMed ID: 2190793
[TBL] [Abstract][Full Text] [Related]
71. Angiogenesis and angiogenesis inhibitors in cancer.
Giavazzi R; Taraboletti G
Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172
[TBL] [Abstract][Full Text] [Related]
72. Current and Emerging Therapeutics for the Management of Endometriosis.
Ferrero S; Barra F; Leone Roberti Maggiore U
Drugs; 2018 Jul; 78(10):995-1012. PubMed ID: 29946962
[TBL] [Abstract][Full Text] [Related]
73. Pleiotropic effects of statins: new therapeutic targets in drug design.
Bedi O; Dhawan V; Sharma PL; Kumar P
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):695-712. PubMed ID: 27146293
[TBL] [Abstract][Full Text] [Related]
74. Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model.
Ceyhan ST; Onguru O; Fidan U; Ide T; Yaman H; Kilic S; Baser I
Eur J Obstet Gynecol Reprod Biol; 2011 Jan; 154(1):100-4. PubMed ID: 21035240
[TBL] [Abstract][Full Text] [Related]
75. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.
Pasqualetti G; Danesi R; Del Tacca M; Bocci G
Pharmacogenomics; 2007 Jan; 8(1):49-66. PubMed ID: 17187509
[TBL] [Abstract][Full Text] [Related]
76. ENMD-1068, a protease-activated receptor 2 antagonist, inhibits the development of endometriosis in a mouse model.
Wang Y; Lin M; Weng H; Wang X; Yang L; Liu F
Am J Obstet Gynecol; 2014 Jun; 210(6):531.e1-8. PubMed ID: 24495669
[TBL] [Abstract][Full Text] [Related]
77. A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022.
Estole-Casanova LA
Acta Med Philipp; 2024; 58(10):49-64. PubMed ID: 38939420
[TBL] [Abstract][Full Text] [Related]
78. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis.
Clemenza S; Sorbi F; Noci I; Capezzuoli T; Turrini I; Carriero C; Buffi N; Fambrini M; Petraglia F
Best Pract Res Clin Obstet Gynaecol; 2018 Aug; 51():92-101. PubMed ID: 29559388
[TBL] [Abstract][Full Text] [Related]
79. [The therapy of endometriosis. New prospects].
Somigliana E; Chiodini A; Odorizzi MP; Pompei F; Viganò P
Minerva Ginecol; 2003 Feb; 55(1):15-23. PubMed ID: 12598839
[TBL] [Abstract][Full Text] [Related]
80. Antiangiogenic agents are effective inhibitors of endometriosis.
Hull ML; Charnock-Jones DS; Chan CL; Bruner-Tran KL; Osteen KG; Tom BD; Fan TP; Smith SK
J Clin Endocrinol Metab; 2003 Jun; 88(6):2889-99. PubMed ID: 12788903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
